Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Conditions: Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Warts; Human Papillomavirus InfectionInterventions: Biological: Comparator: V505 formulation 1; Drug: Comparator: V505 formulation 2; Drug: Comparator: V505 formulation 2; Biological: Comparator: V505 formulation 3; Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant; Biological: Comparator: Placebo (unspecified)Sponsor: Merck Sharp & Dohme Corp.Completed - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer Vaccine | Gardasil | Genital Warts | Human Papillomavirus (HPV) | Research | Vaccines | Vaginal Cancer | Vulvar Cancer | Warts | Women